|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
FY2021
12 months to Mar 31, 2021
|
|
|---|---|---|---|
| General and administration (Note 17) | |||
| Research and development (Note 17) | |||
| Total operating expenses | |||
| Finance income (Note 2d) | |||
| Transaction costs on derivative warrant liability | |||
| Change in fair value of warrant derivative (Note 12) | |||
| Foreign exchange (gain) loss | |||
| Nonoperating income (expense) | |||
| Net loss for the year | |||
| Cumulative translation adjustment | |||
| Comprehensive loss for the year | |||
| Basic and diluted loss per share for the year (in CAD per share) | |||
| Weighted average number of common shares outstanding (Note 9) (in shares) |
Loading...
